![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Pakianathan D.R.
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.6, Iss.7, 1997-07, pp. : 841-846
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets, Vol. 6, Iss. 8, 2006-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
Current Neuropharmacology, Vol. 16, Iss. 2, 2018-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
To exploit the exploitation of actin by HIV?
Drug Discovery Today, Vol. 9, Iss. 1, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)